LEXICON
No.154 July 27, 2017

Cost-Based Method
原価計算方式

In Japan, NHI prices/reimbursement prices/tariff prices (薬価; yakka ) for new drugs are basically set based on the NHI prices of similar drugs on the market under a rule called the comparator method/similar efficacy comparison method (類似薬効比較方式; ruiji yakko hikaku...

To read the full story

LEXICON

By Takamitsu Sasai

Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…

By Reiji Anasako

Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…

By Takamitsu Sasai

Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

By Takashi Ebisawa

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…